McCartney Colin J L, Duggan Edel, Apatu Emma
Department of Anesthesia, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada.
Reg Anesth Pain Med. 2007 Jul-Aug;32(4):330-8. doi: 10.1016/j.rapm.2007.02.010.
Although clonidine has been shown to prolong analgesia in central neuraxial blocks, its use in peripheral nerve blocks remains controversial. We performed a systematic review of the current literature to determine the benefit of adding clonidine to peripheral nerve blocks.
A systematic, qualitative review of double-blind randomized controlled trials on the benefit of clonidine as an adjunct to peripheral nerve block was performed. Studies were identified by searching PubMed (www.ncbi.nlm.nih.gov/entrez) and EMBASE (www.embase.com) databases (July 1991 to October 2006) for terms related to clonidine as an adjunct to peripheral nerve blocks. Studies were classified as supportive if the use of clonidine demonstrated reduced pain and total analgesic consumption, or prolonged block duration versus negative if no difference was found.
Twenty-seven studies were identified that met the inclusion criteria. Five studies included a systemic control group. The total number of patients reviewed was 1,385. The dose of clonidine varied from 30 to 300 mug. Overall 15 studies supported the use of clonidine as an adjunct to peripheral nerve blocks with 12 studies failing to show a benefit. Based on qualitative analysis, clonidine appeared to prolong analgesia when added to intermediate-acting local anesthetics for axillary and peribulbar blocks.
Clonidine improves duration of analgesia and anesthesia when used as an adjunct to intermediate-acting local anesthetics for some peripheral nerve blocks. Side-effects appear to be limited at doses up to 150 mug. Evidence is lacking for the use of clonidine as an adjunct to local anesthetics for continuous catheter techniques. Further research is required to examine the peripheral analgesic mechanism of clonidine.
尽管可乐定已被证明可延长中枢神经阻滞的镇痛时间,但其在周围神经阻滞中的应用仍存在争议。我们对当前文献进行了系统回顾,以确定在周围神经阻滞中添加可乐定的益处。
对可乐定作为周围神经阻滞辅助药物益处的双盲随机对照试验进行了系统的定性回顾。通过检索PubMed(www.ncbi.nlm.nih.gov/entrez)和EMBASE(www.embase.com)数据库(1991年7月至2006年10月)中与可乐定作为周围神经阻滞辅助药物相关的术语来识别研究。如果使用可乐定显示疼痛减轻、总镇痛药物消耗量减少或阻滞持续时间延长,则研究被归类为支持性研究;如果未发现差异,则为阴性研究。
确定了27项符合纳入标准的研究。5项研究包括一个全身对照组。审查的患者总数为1385例。可乐定的剂量从30微克到300微克不等。总体而言,15项研究支持将可乐定用作周围神经阻滞的辅助药物,12项研究未显示出益处。基于定性分析,当可乐定添加到用于腋路和球周阻滞的中效局麻药中时,似乎可延长镇痛时间。
当可乐定作为中效局麻药的辅助药物用于某些周围神经阻滞时,可改善镇痛和麻醉持续时间。在剂量高达150微克时,副作用似乎有限。缺乏可乐定作为连续导管技术局麻药辅助药物的证据。需要进一步研究来探讨可乐定的外周镇痛机制。